Disorders of purine nucleotide degradation include immunodeficiency, myopathy, renal calculi, hyperuricemia and gout, anemia, central nervous system dysfunction, and tissue hypoxia. Disease processes range from rare inborn errors of metabolism to common clinical abnormalities associated with tissue hypoxia and depletion of ATP. Two major types of disorders occur in this pathway: blocks of purine nucleotide degradation and increased activity of this pathway. In the present proposal, we will test the hypothesis that accelerated ATP degradation in humans accounts for the formation of increased purine nucleotide degradation products in specific disorders. We will approach this study by (a) Establishing whether accelerated ATP degradation is involved in the pathophysiology of ethanol-induced alterations of purine metabolism, carbohydrate-induced alterations of purine metabolism, elevated body fluid purines in acute illness and metabolic myopathies; (b) Studying a cell culture model to elucidate mechanisms regulating ATP degradation at the cellular level using a model of purine nucleotide degradation; and (c) Determining whether cytoplasmic 5'-nucleotidase has an important regulatory role in purine nucleotide degradation. This integrated approach involves a study on three levels, the patient, the cell and an enzyme and should provide a unique opportunity to test the hypothesis and its implications. The laboratory will continue to be a resource by providing assays of enzymes of purine metabolism for diagnosing inborn errors and by assisting investigators with studies of disorders of purine metabolism. The methods of procedure will include affinity techniques, high pressure liquid chromatography, cell culture, and new methods which we have developed to study purine nucleotide degradation in humans. By elucidating the role of accelerated ATP degradation in human disease, we may facilitate the design of innovative therapeutic approaches for stimulating adenine nucleotide synthesis in these disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM019674-08
Application #
3151243
Study Section
Biochemistry Study Section (BIO)
Project Start
1977-01-01
Project End
1986-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
8
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Madrid-Marina, V; Lestan, B; Nowak, P J et al. (1993) Altered properties of human T-lymphoblast soluble low Km 5'-nucleotidase: comparison with B-lymphoblast enzyme. Leuk Res 17:231-40
Lin, H Y; Rocher, L L; McQuillan, M A et al. (1989) Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients. Adv Exp Med Biol 253A:289-92
Lin, H Y; Rocher, L L; McQuillan, M A et al. (1989) Cyclosporine-induced hyperuricemia and gout. N Engl J Med 321:287-92
Spychala, J; Fox, I H (1989) The application of affinity chromatography for the separation of ""high Km"" and ""low Km"" 5'-nucleotidase and other AMP metabolizing enzymes. Adv Exp Med Biol 253B:119-27
Spychala, J; Madrid-Marina, V; Fox, I H (1989) Evidence for ""low Km"" and ""high Km"" soluble 5'-nucleotidases in human tissues and rat liver. Adv Exp Med Biol 253B:129-34
Puig, J G; Jimenez, M L; Mateos, F A et al. (1989) Adenine nucleotide turnover in hypoxanthine-guanine phosphoribosyl-transferase deficiency: evidence for an increased contribution of purine biosynthesis de novo. Metabolism 38:410-8
Tekkanat, K K; Fox, I H (1988) Isocratic separation of ATP and its degradation products from biological fluids by automated liquid chromatography. Clin Chem 34:925-32
Spychala, J; Madrid-Marina, V; Fox, I H (1988) High Km soluble 5'-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J Biol Chem 263:18759-65
Tekkanat, K K; Port, F K; Schmaltz, S et al. (1988) Excessive ATP degradation during hemodialysis against sodium acetate. J Lab Clin Med 112:686-93
Mateos, F A; Puig, J G; Jimenez, M L et al. (1987) Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage. J Clin Invest 79:847-52

Showing the most recent 10 out of 23 publications